VIB INKS QBASE+ GROUP LICENSING AGREEMENT WITH BIOGAZELLE: http://t.co/EkimyQQSZW
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Promethera® Biosciences an innovative stem cell therapy company dedicated to liver regenerative medicine announces that Dr. Beatrice De Vos joined the company to lead its Clinical Research & Medical Affairs team. She joined Promethera® Biosciences SA from January 1, 2011 as Chief Medical Officer.
Eric Halioua, CEO at Promethera® Biosciences, says: “We are very pleased to welcome Beatrice De Vos who is going to play a key role in developing Promethera® Biosciences clinical research organization. Dr De Vos has the experience and expertise we were looking for to strengthen our management team. With nearly 20 years of multinational experience in clinical and scientific research she will build the medical department and lead the first clinical trials with Promethera® Hepastem ”.
Beatrice De Vos, MD, BCPM is a native Belgian board certified medical doctor and specialist in pharmaceutical medicine. She trained at the Catholic University of Leuven (KUL) and at Erasme University of Brussels. She is a member of the Belgian College of Pharmaceutical Medicine (BCPM). For the past 19 years she worked in leading positions of clinical research and medical affairs departments of major international pharmaceutical companies (Wyeth-Ayerst R&D, GSK Bio, Sanofi Pasteur). She was in charge of the clinical development programs of multiple drug candidates in a variety of therapeutic fields and responsible for the global development of several viral vaccine candidates. She succeeded to develop a rotavirus vaccine for new-borns from bench to bed (Rotarix®). She was the originator of a public private partnership’s (WHO, USAID, NIH, CVP, CDC, and GSKBio) initiative to accelerate the development and availability of rotavirus vaccines in the developing world (RAPID: Rotavirus action program for immunization and development). Today, she has more than 20 publications in international peer-reviewed journals and books. She is an invited lecturer at the University of Antwerp, Institut Pasteur (Paris), Fondation Mérieux, University of Aveiro (Portugal), and speaker at several national and international scientific congresses. Before joining Promethera® Biosciences as CMO, she was Vice President Global Medical Affairs at GSK Biologicals based at headquarters in Rixensart, Belgium and VP Global Medical & Scientific Affairs at Sanofi Pasteur, the vaccine division of Sanofi Aventis, based at headquarters in Lyon, France.
Dr. Beatrice De Vos, CMO at Promethera® Biosciences, says: “It is with great pleasure that I join Promethera Biosciences. I am convinced that in close collaboration with Prof Etienne Sokal, Chief Scientific Officer, we will be successful in bringing this breakthrough technology to the patients, for their greatest benefit, and add value for Promethera® Biosciences’ Shareholders.”
Promethera® Biosciences’ mission is to discover, develop and commercialize cell therapy products so that liver diseases can be treated using allogeneic stem cells isolated from healthy human livers. Promethera® Biosciences intends to bring two different products to the market: Promethera® HepaStem and Promethera® HepaScreen. The cell therapy product Promethera® HepaStem is based on a newly discovered and proprietary progenitor cell type: Human Adult Liver Derived Mesenchymal Stem Cells (hALDMSC) which can be used to cure a wide variety of liver diseases, from rare inborn metabolic diseases (orphan diseases), to larger acquired liver deficiencies such as liver fibrosis or fulminant hepatitis. The treatment has already received two orphan drug designations from the European Medicines Agency for the treatment of very debilitating pathologies affecting children and will be further developed to offer to these patients a real curative treatment. The same cell product developed as Promethera® HepaScreen will serve as a cell model for discovery as well as for pre-clinical departments of the pharmaceutical and biotechnology industry to mimic metabolism and detoxification of new drugs by the human liver.
Source: Promethera Biosciences